Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. (5th July 2021)

• Record Type: Journal Article
• Authors: Gru, Alejandro A.; Bacchi, Carlos E.; Pulitzer, Melissa; Bhagat, Govind; Kempf, Werner; Robson, Alistair; Plaza, Jose A.; Pincus, Laura; Raghavan, Shyam; Xu, Mina; Vencato da Silva, Tiago; Salavaggione, Andrea L.; Subtil, Antonio; Battistella, Maxime
• Is Part Of: Journal of cutaneous pathology. Volume 48:Number 11(2021)
• Page Start: 1367
• Page End: 1378
• Publication Date: 2021-07-05
• Subjects: cutaneous lymphoma -- Hodgkin lymphoma -- skin involvement; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.14077
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Background: Cutaneous involvement by classic Hodgkin lymphoma (CHL) is an extraordinarily rare phenomenon in the current era. To date, no single large case series of cutaneous involvement by Hodgkin lymphoma has ever been reported in the literature. Methods: A comprehensive search for cases designated "skin" and "Hodgkin" was performed at different institutions between 1990 and 2020. Twenty‐five cases were identified, and each case was independently reviewed by at least three board‐certified dermatopathologists and/or hematopathologists. Results: All cases represented examples of systemic CHL with secondary skin dissemination. A single lesion, usually a tumor, nodule or infiltrative plaque was observed in 56% of cases and multiple lesions were present in 28% of cases. Most patients (86%—12/14) had a diagnosis of stage IV disease at first diagnosis. The interval between the clinical (first) diagnosis of HL and the development of skin lesions ranged between 6 and 108 months (average 33.75 months). Comprehensive histopathologic evaluation of these cases (at the initial diagnosis) revealed a diagnosis of classic HL not otherwise specified (NOS) in 60% of cases (15/25), nodular sclerosis type in 24% (6/25), mixed cellularity in 12% (3/25), and lymphocyte depleted in 4% (1/25). Conclusions: We provide documentation of a large series of CHL with secondary skin involvement in association with CHL with additional clinical, morphologic, and immunophenotypic features.